Recent

% | $
Quotes you view appear here for quick access.

Velti Halka Acık Limited Şirket Message Board

cash2go 64 posts  |  Last Activity: Jul 11, 2016 1:44 PM Member since: Feb 8, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Peer reviewed article out today

    by cash2go Jul 8, 2016 9:34 AM
    cash2go cash2go Jul 11, 2016 1:44 PM Flag

    Emerging Treatments for SCD June 14, 2016 - for anyone interested doing their own research

  • Reply to

    Peer reviewed article out today

    by cash2go Jul 8, 2016 9:34 AM
    cash2go cash2go Jul 11, 2016 1:41 PM Flag

    Note for Favus;

    Prior O2 modulators have been very beneficial in improving the disease state. The problem is that they were limited by toxicity and PK. Decreasing painful crises incidences by 80%. Other benefits seen along with decrease in pain.

    We know seem to have a once daily oral drug that has a high affinity for hemoglobin and MINIMAL side effects.

    After a great 6 months of promising data, looking forward to the Favus update for the Hedgies he advised to go short last year.

  • #1 Consolidate while doing the hard work from K-Street, usually works. In an election year it will be much harder to slip the 'ole consolidation trick past the public.

  • Reply to

    Peer reviewed article out today

    by cash2go Jul 8, 2016 9:34 AM
    cash2go cash2go Jul 11, 2016 12:50 PM Flag

    Elliot Favus still bashing Global Therapeutics? More likely the news leaking out the past few weeks has pi$$id off the hedges he charges for his "insights".
    " hiding 90-day data", LMAO

  • British Journal of Hematology, nice conservative review. For those following the story there is even more info known info being reviewed, buying all news giving Brexit dips that effect GBT.

    GLTA

  • Investors that have done their research are now buying as advanced data is released.
    What is likely up next?
    Among the “2016 Anticipated Milestones” you will find:

    Hereditary Angioedema: Complete IND-enabling toxicology studies, submit an IND, and initiate a Phase 1 study for GBT18713, an orally bioavailable kallikrein inhibitor. Expected to start in 2016.

    Another promising pipeline drug the company has hight expectations for and would like to some complete research on before being bought out at too cheap of a price.

  • Global Blood Therapeutics likely has an equally interested domestic buyout? Whoever they pick up will need a knowledgeable worldwide sales force. Any company interested needs to close the deal before "Breakthrough Status" or "accelerated approval" is granted. The price of a buyout will be MUCH higher.

    2017 is not that far away and would be much better for tax purposes of many

  • Reply to

    Brett -vs- a lot of good news

    by cash2go Jun 30, 2016 9:00 AM
    cash2go cash2go Jun 30, 2016 9:02 AM Flag

    "Brexit" -vs a lot of good news... darn autocorrect

  • Sickle Cell wins and hope to see a new drug with breakthrough status and accelerated approval by end of year. Unmet need demands it. 2017 will be a very good year.

  • cash2go by cash2go Jun 24, 2016 3:22 PM Flag

    Deerfield Management now over 5%

  • cash2go cash2go Jun 24, 2016 11:11 AM Flag

    IPAB is focused on saving health dollars and will continue to meet annually.

    SCD is also associated with high treatment costs. One study estimated that in the United States, the average annual cost for the care of an adult patient with the most common genotype of SCD exceeds $200,000. This equates to cumulative lifetime costs in excess of $8.0 million over an assumed 50-year lifespan, driven primarily by hospital admissions, physician fees, clinic and emergency department visits, and the costs of diagnostic procedures and outpatient consultations.

    * Hold on small investors, the big boys will collect shares then drop the price lower (on Brexit concerns) so keep in your low bids and wait for the buyers to step back. Gulp, planned a plan and that was to get shares at much lower prices today, day is not over.

    GLTA

  • cash2go cash2go Jun 23, 2016 7:57 PM Flag

    The Funds will be buying at the end of the session. You can get fireworks as they must buy at the close no matter the price. A sellers stake would be nice, If holders ask for $3 and above that is where the stock will go.
    ((IF)) the price hits $3 I will sell. Hope all holders put in asks that are much higher. I've benefitted greatly from the rebalancing in the past.

    GLTA, it will all hit in the last few minutes.

  • cash2go cash2go Jun 23, 2016 4:15 PM Flag

    Also, why did Biotech (the IBB) recently crash hard to start recovering?

    The BAD:
    Why Biotech is Getting Crushed
    Ben Levisohn at Barrons

    On April 25th we wrote a report on IPAB, which stands for the Medicare Independent Payment Advisory Board. This is the entity that, under certain circumstances, has the power to propose/implement cuts to the Medicare program if a certain spending threshold (the “trigger”) is met. We said that the trigger determination would likely occur somewhere in the late May to July timeframe.

    Our latest information is that the trigger update is likely to come this week per industry contacts

    The Good:
    IPAB made a ruling yesterday and cuts in prices paid for the many overpriced drugs did not hit the threshold, not cut for Big Pharma. GBT440 would not have been a drug that would have seen cuts if IPAB decided to cut reimbursement on the many me-too and worthless drugs we overpay for. I was rooting for IPAB to make needed cuts on overpriced and questionable drugs. I am also long GBT because it is a very impressive and needed drug that IPAB cuts would not target.

  • cash2go cash2go Jun 23, 2016 3:56 PM Flag

    2017 should be a very good year for GBT and it's shareholders.

  • cash2go cash2go Jun 23, 2016 3:54 PM Flag

    Not selling at $27. This stock has a drug that has the potential to greatly reduce to cost of Sickle Cell therapy.

  • cash2go cash2go Jun 23, 2016 3:47 PM Flag

    Sickle cell patients live 25 to 30 years less than average. The pain associated with hypoxia in vital drugs is severe and hospitalization is required. Give me a cancer drug that gives patients 5 months extra of questionable quality life and you have a $5B drug.

    Holding cash and slowly add as the spiral may not have finished. Margin clerks and Brexit and the Russell rebalance on Friday. It's been the perfect storm for those new to this stock.

  • Reply to

    90-Day Data Show Sustained Treatment Response

    by cash2go Jun 23, 2016 11:47 AM
    cash2go cash2go Jun 23, 2016 11:55 AM Flag

    Raising funds during Brexit and and a biotech nosedive was a no brainer when you are focused on patients and getting a possible "breakthrough" drug to the market. When will the pediatric phase I trials start?

    Thank you to Brexit and Margin calling Divas for my $17 shares. Think Obama would like this one to gain accelerated approval and compassionate use availability before he leaves office?

    For those new to biotech "Fast Track" is something every company that comes up with a drug idea gets simply by filling out the application

  • Big Deal?
    All SCD patients dosed with GBT440 have shown a positive hematologic response. Additionally, a rapid and durable reduction in hemolytic anemia and sickling has been shown over 90 days. We continue to see a linear, dose proportional relationship between pharmacokinetics and pharmacodynamics, and the data continue to support the inhibition of polymerization of sickle hemoglobin through increased oxygen affinity as the mechanism of action of GBT440

    From Eyeing Biotech, analyst looking at medical advancements not Wall Street BS

    It is important to remember that healthy red blood cells have a lifespan of 90-120 days (SCD RBCs lifespan is much shorter) and hemoglobin is stable with low turnover rates so the drug is acting on a population of cells (and hemoglobin) that will only have a small fraction turned over at the 28 day marker if sickling is prevented and therefore expanding the life time of the RBCs.

    The entire article is well worth reading. It was written before 90 dat data that got me interested in this one as a long term investment.

  • Reply to

    Why Biotech is Getting Crushed

    by cash2go Jun 21, 2016 7:37 PM
    cash2go cash2go Jun 21, 2016 7:49 PM Flag

    Too many me-too drugs (costly as it is usually used to replace drugs going off patent) and price gouging whenever possible. Then we have these genetic therapies that cost hundreds of thousands. Next you have these scary stats:
    27 to 30 percent of Medicare payments cover the cost of care for people in the last year of life. 40 percent of Medicare dollars cover care for people in the last month. 12 percent of Medicare spending covers people who are in the last two months.

    Something needs to be done, it's going to be complicated and controversial. We have no choice unless we are willing to cut a few of those billion dollar planes, tanks and ships from the budget, you know that military industrial complex that Eisenhower warned us about.

  • Ben Levisohn at Barrons

    On April 25th we wrote a report on IPAB, which stands for the Medicare Independent Payment Advisory Board. This is the entity that, under certain circumstances, has the power to propose/implement cuts to the Medicare program if a certain spending threshold (the “trigger”) is met. We said that the trigger determination would likely occur somewhere in the late May to July timeframe.

    Our latest information is that the trigger update is likely to come this week per industry contacts.